Japan Idiopathic Pulmonary Fibrosis Treatment Market to Grow at 7.4% During 2025-2033, Impelled by Increasing Geriatric Population

January 27, 2025 | Healthcare

According to the latest report by IMARC Group, titled "Japan Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2025-2033," the Japan idiopathic pulmonary fibrosis treatment market size reached USD 181.0 Million in 2024. Idiopathic pulmonary fibrosis (IPF) refers to a medical condition that causes the lungs to become scarred, which leads to breathing difficulties. This condition is a serious lung disease, which causes the growth of scar tissues inside the lungs and slows the oxygen flow to the bloodstream, leading to a persistent dry cough, loss of appetite and weight, rounded and swollen fingertips and shortness of breath. Its diagnosis includes breathing and blood tests, chest X-ray and computed tomography (CT) scan, bronchoscopy and lung biopsy. The treatment for this condition involves oxygen therapy, pulmonary rehabilitation, lung transplant and anti-fibrotic drugs that aid in slowing lung damage and improving the quality of life.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The market in Japan is primarily driven by the growing prevalence of idiopathic pulmonary fibrosis among the masses. Coupled with the increasing geriatric population, which is more prone to medical ailments, this is creating a positive market outlook. Along with this, the growing commercialization of novel drugs and the increasing awareness regarding IPF and its available treatments among individuals are providing a boost to the market growth. Moreover, the rising investments by key players in extensive research and development (R&D) activities to introduce new treatment approaches are impacting the market favorably across the country. Additionally, numerous initiatives undertaken by the government to promote and create awareness regarding IPF disease are significantly supporting the demand for IPF treatments among individuals. Other factors, including the growing number of clinical trials, continuous improvements in the healthcare infrastructure, the inflating disposable income levels of the masses and continual technological advancements in the healthcare sector, are also positively influencing the market across Japan. Looking forward, the market value is projected to reach USD 345.0 Million by 2033, expanding at a CAGR of 7.4% during 2025-2033.

Market Summary:

  • On the basis of the drug class, the market has been segmented into MAPK, tyrosine and autotaxin inhibitors.
  • Based on the end-user, the market has been segregated into hospitals, long-term care facilities and others.
  • On the basis of the region, the market has been divided into Kanto, Kinki, Central/ Chubu, Kyushu-Okinawa, Tohoku, Chugoku, Hokkaido and Shikoku regions.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
     

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Million USD
Segment Coverage Drug Class, End User, Region
Region Covered Kanto Region, Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Japan Idiopathic Pulmonary Fibrosis Treatment Market to Grow at 7.4% During 2025-2033, Impelled by Increasing Geriatric Population
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials